Ermium Therapeutics announces the execution of a collaboration agreement with Erganeo and University of Paris. This collaboration agreement will allow Jean-Philippe Herbeuval, scientific founder of Ermium Therapeutics, and co-workers at UMR8601 (laboratory headed by Jean-Philippe Herbeuval at CNRS and University of Paris) to gain a deeper understanding of the mechanism of action of CXCR4 agonists with anti-inflammatory activities.
Ermium Therapeutics, Erganeo & Université of Paris
Share
Share on twitter
Share on linkedin
Share on whatsapp
Share on email